机构：[1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P.R. China.河北医科大学第四医院
出处：
ISSN：
摘要：
The purpose of this study was to examine whether combined cisplatin and late course accelerated fractionation radiotherapy (LCAH) (the combined group) can confer a better outcome over LCAH alone in treating esophageal carcinoma. Eighty-one eligible patients were randomly entered into two groups: the LCAH alone group, and the combined group. There was a better outcome in the combined group compared to the LCAH group, but the difference was not significant. The combined therapy could significantly improve the survival rate and local control of the disease in the early stage, but not in the advanced stage, because of the possibility of invasion. More severe complications occurred in the combined group than in the LCAH group, but they were within tolerance. In conclusion, LCAH concomitant with cisplatin could improve the survival of patients with esophageal cancer, especially in the early stage, as long as the side effects of the treatment are within tolerable limits.
语种：
外文
PubmedID：
中科院分区：
出版当年[2020]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2025]版：
大类|3 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, P.R. China.
推荐引用方式(GB/T 7714)：
Gao Xian-Shu,Qiao Xue-Ying,Yang Xiang-Ran,et al.Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma.[J].Oncology Reports.2020,9(4):767-72.
APA：
Gao Xian-Shu,Qiao Xue-Ying,Yang Xiang-Ran,Asaumi Jun-Ichi,Zhou Zhi-Guo...&Hiraki Yoshio.(2020).Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma..Oncology Reports,9,(4)
MLA：
Gao Xian-Shu,et al."Late course accelerated hyperfractionation radiotherapy concomitant with cisplatin in patients with esophageal carcinoma.".Oncology Reports 9..4(2020):767-72
